Patent ID: 8951795
Filing Date: 2015-02-10
Classification: A61K,A61P,C12N

Abstract:
1. A diagnostic agent for cancer localization, comprising a cell population with a revascularization ability, expressing CD11b, CD31, CXCR4, CD14, CD105, CD146, VEGF receptor 2, and G-CSF receptor, obtained by inducing differentiation of a mononuclear cell population by culturing the mononuclear cell population in a serum free medium containing one or more selected from vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), thrombopoietin (TPO), granulocyte-colony stimulating factor (G-CSF) and FMS-like tyrosine kinase 3 ligand (FLT3L), wherein: the mononuclear cell population is a human mononuclear cell population; and the cell population with the revascularization ability, expressing CD11b, CD31, CXCR4, CD14, CD105, CD146, VEGF receptor 2, and G-CSF receptor, has selective tropism to one or more of tumor tissue or ischemic zones.